New combo attack on hard-to-treat prostate cancer shows promise

This study tested whether adding a precise, high-dose radiation treatment (SBRT) to the hormone therapy apalutamide helps control prostate cancer that has stopped responding to standard hormone therapy and spread to a few spots. Twenty-six men with this type of cancer took part. The main goal was to see if the combination could make PSA levels undetectable after 18 months. The approach aims to delay the cancer's progression while keeping side effects manageable.